China Developers Broadening Global TPD Landscape

Lead Assets Move To Phase III

 
• By Xu Hu

Multiple Chinese companies are progressing targeted protein degraders, with oncology the dominant indication and two assets already in Phase III for breast cancer.

Ubiquitin is attached to target proteins for the ubiquitination process
(Shutterstock)
Xu Hu

Read more by Xu Hu

Xu is a senior reporter and covers aspects on policy and regulations in China pharma industry within the APAC Pharma news team.

More from Clinical Trials

More from R&D